Ezra R. Lowe, Ph.D.

Ezra R. Lowe, Ph.D., is a pharmaceutical R&D executive with more than 20 years of experience leading global drug development across the biotech and pharmaceutical sectors. He has extensive expertise spanning clinical pharmacology, translational medicine, and regulatory strategy, with a track record of advancing programs from preclinical development through regulatory approval.

Most recently, Dr. Lowe served as Vice President of Clinical Pharmacology and Preclinical R&D at Galectin Therapeutics, where he led multidisciplinary teams and external partners to support clinical and preclinical development programs, including IND submissions and the advancement of a novel therapy in oncology and liver disease. Prior to Galectin, he held roles of increasing responsibility at Bausch Health, where he oversaw clinical pharmacology strategies across a broad portfolio of programs and contributed to multiple successful regulatory submissions and product approvals.

Earlier in his career, Dr. Lowe held scientific roles at Salix Pharmaceuticals, Bausch + Lomb and The Dow Chemical Company, where he built deep expertise in drug metabolism, pharmacokinetics, and bioanalytical sciences. Across his career, he has contributed to more than 50 drug development programs, supporting 13 regulatory approvals globally, and has authored numerous scientific publications and patent applications.

Dr. Lowe received his Ph.D. in Pharmacology from the University of Michigan and his B.A. in Chemistry from Colgate University.